<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>http://hboevidence.wikis.unsw.edu.au/index.php?action=history&amp;feed=atom&amp;title=Ward</id>
	<title>Ward - Revision history</title>
	<link rel="self" type="application/atom+xml" href="http://hboevidence.wikis.unsw.edu.au/index.php?action=history&amp;feed=atom&amp;title=Ward"/>
	<link rel="alternate" type="text/html" href="http://hboevidence.wikis.unsw.edu.au/index.php?title=Ward&amp;action=history"/>
	<updated>2026-10-04T18:00:42Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.31.0</generator>
	<entry>
		<id>http://hboevidence.wikis.unsw.edu.au/index.php?title=Ward&amp;diff=262&amp;oldid=prev</id>
		<title>Gordoben: Imported from Wikispaces</title>
		<link rel="alternate" type="text/html" href="http://hboevidence.wikis.unsw.edu.au/index.php?title=Ward&amp;diff=262&amp;oldid=prev"/>
		<updated>2011-12-31T02:41:33Z</updated>

		<summary type="html">&lt;p&gt;Imported from Wikispaces&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 130%;&amp;quot;&amp;gt;'''There was no benefit in terms of survival or radiation morbidity when hyperbaric oxygen was added to a radiotherapy regime for treatment of advanced carcinoma of the cervix.''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Clinical Bottom Line:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. No improvement in 5 year survival with the addition of hyperbaric oxyygen. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;2. There was no reduction in the incidence of metastases or local recurrence. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;3. There was a trend to increased radiotherapy-related morbidity associated with hyperbaric oxygen. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Appraised by:''' Mike Bennett, Dept of Diving and Hyperbaric Medicine, Prince of Wales Hospital &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Sydney; Wednesday, 17 February, 1999 &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Clinical Scenario:''' A patient with stage III carcinoma of the cervix presented for radiotherapy. '''Three-part Question:''' In treating advanced cervical carcinoma with radiotherapy, does the addition of hyperbaric oxygenation during irradiation result in any improvement in survival? &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Search Terms:''' Hyperbaric oxygenation, carcinoma of the cervix &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''The Study:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Non-blinded randomised controlled trial without intention-to-treat. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Patients with advanced carcinoma of the cervix (Stages IIb and III), in whom radiotherapy was considered the treatment of choice. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Control group (N = 48; 47 analysed): Three 'Cathetron' implants for radiotherapy at two weekly intervals with 10 external fractions bracketed around the second insertion to a total dose of 6,000rads. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Experimental group (N = 39; 36 analysed): As above, but external beam irradiation given while receiving hyperbaric oxygenation (dose not stated). &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''The Evidence:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| &lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Outcome''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Time to Outcome''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Air group''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''HBO group''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Relative risk increase''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Absolute risk increase''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''NNH''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Radiation morbidity''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;2 years &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.13 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.22 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;69% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.09 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;11 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''95% CI:''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; ||   ||   ||   || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;55% to 100% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-0.07 to 0.25 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;NNT'''14 to INF NNH'''4 to INF &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''death''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;5 years &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;.54 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;.62 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;15% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.08 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;12 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''95% CI:''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; ||   ||   ||   || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;24% to 53% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-0.13 to 0.29 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;NNT'''3 to INF NNH'''8 to INF &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Comments:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. 5 patients were analysed in the air group when randomised to receive hyperbaric oxygen. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;2. Patients not completing therapy were excluded from analysis. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;3. Survival figures were not given in the text, but read off the figure. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;4. This study follows on from Watson et al with a change in radiotherapy regime. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Expiry date:'''January 2004 &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''References:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: arial,helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. Ward AJ, Dixon B. Carcinoma of the cervix: results of a hyperbaric oxygen trial associated with the use of the Cathetron. Clinical Radiology 1979; 30:383-387. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: arial,helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;2. Ward AJ, Dixon B, Stubbs B. A clinical appraisal of hyperbaric oxygen in cervix cancer. Proceedings of The British Institute of Radiotherapy 1978;51:150-151.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&lt;br /&gt;
[[File:http://www.hboevidence.com/_themes/copy-of-sumi-painting/sumhorsa.gif]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color: #7c00ff; display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style=&amp;quot;color: #7c00ff; font-family: Arial,Helvetica,sans-serif; font-size: 26px;&amp;quot;&amp;gt;[[DXRTpelvis  |  BACK]]&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt;&lt;/div&gt;</summary>
		<author><name>Gordoben</name></author>
		
	</entry>
</feed>